September 08, 2008 - The results indicate that IN-105 is safe and well tolerated by Type 2 diabetic patients and is able to significantly drop 2-hour post prandial glucose in a dose-related manner - Biocon Limited, India’s premier biotechnology company, announced the results of an ascending dose study with their oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome on September 8, 2008. The study involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety and tolerability of IN-105, as well as the pharmacokinetics and pharmacodynamics of IN-105. The results showed that IN-105 was safe and well tolerated by patients... Biocon's Press Release -
Thursday, October 2, 2008
Biocon : Human Clinical Data on IN-105 (Oral Insulin) at the EASD Meeting in Rome
September 08, 2008 - The results indicate that IN-105 is safe and well tolerated by Type 2 diabetic patients and is able to significantly drop 2-hour post prandial glucose in a dose-related manner - Biocon Limited, India’s premier biotechnology company, announced the results of an ascending dose study with their oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome on September 8, 2008. The study involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety and tolerability of IN-105, as well as the pharmacokinetics and pharmacodynamics of IN-105. The results showed that IN-105 was safe and well tolerated by patients... Biocon's Press Release -
